New Insights into Ion Channels: Predicting hERG-Drug Interactions

Michael Fitzpatrick Wempe

1 Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado—Anschutz Medical Campus, Aurora, CO 80045, USA; michael.wempe@cuanschutz.edu; Tel.: +1-303-724-8982
2 University of Colorado Cancer Center, University of Colorado—Anschutz Medical Campus, Aurora, CO 80045, USA

Abstract: Drug-induced long QT syndrome can be a very dangerous side effect of existing and developmental drugs. In this work, a model proposed two decades ago addressing the ion specificity of potassium channels is extended to the human ether-à-gogo gene (hERG). hERG encodes the protein that assembles into the potassium channel responsible for the delayed rectifier current in ventricular cardiac myocytes that is often targeted by drugs associated with QT prolongation. The predictive value of this model can guide a rational drug design decision early in the drug development process and enhance NCE (New Chemical Entity) retention. Small molecule drugs containing a nitrogen that can be protonated to afford a formal +1 charge can interact with hERG to prevent the repolarization of outward rectifier currents. Low-level ab initio calculations are employed to generate electronic features of the drug molecules that are known to interact with hERG. These calculations were employed to generate structure–activity relationships (SAR) that predict whether a small molecule drug containing a protonated nitrogen has the potential to interact with and inhibit the activity of the hERG potassium channels of the heart. The model of the mechanism underlying the ion specificity of potassium channels offers predictive value toward optimizing drug design and, therefore, minimizes the effort and expense invested in compounds with the potential for life-threatening inhibitory activity of the hERG potassium channel.

Keywords: potassium channel; human ether-à-gogo-related gene (hERG); structure–activity relationships (SAR); ab initio calculations; drug development; long QT syndrome; Torsades de Pointes

1. Introduction

While recent studies on potassium channels have expanded our understanding of their structure and function, there were three physiochemical phenomena whose underlying mechanism remained to be explained: (1) the selectivity for K⁺ despite higher extracellular levels of Na⁺, (2) pore selectivity being enforced despite the larger size of the potassium ion compared to the sodium ion, and (3) the TEA (tetraethyl ammonium cation) being an effective inhibitor of potassium channels, whereas the smaller TMA (tetramethyl ammonium cation) has little to no effect despite the intuitive notion that its smaller size might permit deeper penetration in the pore. One explanation for these phenomena was proposed in a previously presented model [1].

The model addresses the ion specificity of potassium channels by noting that an m/z relationship exists for quaternary ammonium (QA) ions. An analogy to quadrupole mass spectrometry (QMS) was proposed [1]. Potassium channels have four alpha-subunits (Figure 1A; [2]) with a membrane potential. In QMS, there are four parallel rods with two opposite rods having an applied potential of [U+Vcos(wt)] and the other two are [-U+Vcos(wt)], where Vcos(wt) is an ac voltage while U is a dc voltage (Figure 1B) [3,4]. Applied voltages influence the ion trajectory traversing down the channel. Thus, in QMS, the ion beam is directed in a longitudinal direction and resides between four parallel
opposite rods with their phases shifted 180 degrees from one another; they are superimposed by a high-frequency field. In the case of a pre-defined current, only particles of a particular \( m/z \) will reach the outer slot. The gating kinetics regarding potassium channels are multifaceted \([5–7]\); the fact that it is generally accepted that all voltage-gated potassium channels have essentially the same pore construction allows one to extend the QA ion model proposed previously \([1]\) to predict drug-hERG inhibition. One investigates the charge on the protonated nitrogen, the alkyl environment surrounding the protonated amine, and then the aromatic skeleton found within the drug substance.

![Diagram of a potassium channel](image)

**Figure 1.** (A) Representative depiction of an extracellular view of a voltage-gated potassium channel. Ribbon representation of the hERG channel. The image was generated using Schrödinger Maestro and importing the PDB: 5VA1 3.70 Å structure \([2]\), including the biological unit. The ribbons are colored by residue position using the default palette in Schrödinger Maestro. (B) Representative sketch of a mass spectrometry quadrupole.

1.1. hERG and Potassium Channel History

In 1994, Warmke and Ganetzky \([8]\) recognized the novel human cDNA, now known as the human ether-à-gogo-related gene (hERG). Located in human ventricles and human
atria, the hERG encodes the potassium channel responsible for the delayed rectifier current Ikr [9,10]. The repolarization of cardiac myocytes can be triggered by the activation of outward potassium ion currents and involves the delayed rectifier current (IK). The delayed rectifier current contains two components, Ikr and Iks. Many drugs associated with QT prolongation have been shown to block Ikr and/or the cloned hERG channel. Therefore, understanding the molecular and physicochemical mechanisms involved in voltage-gated potassium channels is important.

Potassium channels are water-solvated proteins that allow certain ions to pass through the pore [11] and transport across the lipid bilayer membrane. All potassium channels have nearly the same pore construction as shown by molecular cloning and mutagenesis studies. Biophysical data support the notion that the potassium channel pore region possesses multiple binding sites, has a high affinity for K\(^{+}\), and acts as a selectivity filter [12]. The four \(\alpha\)-subunits form a cone that cradles the selectivity filter; therefore, K\(^{+}\) channels are long, narrow pore channels that produce an ion flux. Potassium channels may be thousands of times more permeable to K\(^{+}\) than to Na\(^{+}\). Known as the ‘potassium channel signature sequence’, potassium channels contain critical amino acids, and the mutation of these amino acids can disrupt the preference for K\(^{+}\) over Na\(^{+}\) [12].

1.2. Long QT Syndrome

Drug-induced long QT syndrome can be a dangerous side effect of certain prescription drugs. It is commonly accepted that different drugs may prolong cardiac repolarization by blocking one or more types of voltage-gated K\(^{+}\) channels. As a result, drugs that create the prolongation of the QT interval on the electrocardiogram (EKG) can lead to the life-threatening ventricular arrhythmia known as Torsades de Pointes [13]. The fact that all of the known compounds (>95%) which produce these physiological effects contain an amine functionality and the fact that it is generally accepted that all voltage-gated potassium channels have essentially the same pore construction (i.e., four \(\alpha\)-subunits form a cone that cradles the selectivity filter) allow one to extend the QA ion model proposed in 2001 [1] to predict the potential of a drug to inhibit hERG and, therefore, the prospect of drug-induced prolonged QT syndrome.

1.3. Potassium Channel Research and Development

In the past two decades, a number of research groups have addressed issues of K\(^{+}\) channel specificity for ions and inhibitors. Several studies employing a variety of approaches offer insight into hERG and its interactions with drugs and ions. In 2012, Vilums et al. reported an interesting hERG SAR on the inhibitor known as E-4031 [14]. Other researchers performed hERG SAR studies, for example, on dofetilide derivatives [15]. Moreover, in 2013, Louvel et al. [16] reported an SAR around the Clofilium template. Other groups investigated hERG inhibition in a large diverse compound library by performing an automated patch-clamp assay [17]. In addition, Negami et al. [18] computed hERG-drug binding free energies. Recently, a group combined multi-dimensional molecular fingerprints to predict hERG [19]. Butler et al. provided a nice review of the hERG structure [20], providing information regarding mutagenesis studies and channel gating. The current work provides an alternative way of looking at the hERG-drug interactions by looking at the atomic charges on the atoms within molecules, specifically protonated amines. Our hope is that the current methods will help medicinal chemists and preclinical safety scientists with an alternative way to look at hERG-drug interactions early in the New Chemical Entity (NCR) developmental process.

2. Results and Discussion

2.1. Fundamental Concepts: SAR, Drift Speed, and Effective Charge

Models and experiments that assess biological activity as a function of chemical structure are called ‘Structure-Activity Relationships’ (SAR) [21]. SAR models can provide qualitative and/or quantitative predictions that help decipher critical chemical motifs,
chemical mechanism, and chemical trends [22]. Our model proposes that potassium channels segregate ions in a manner analogous to a quadrupole mass spectrometer governed by an m/z relationship. Thus, it is critical to define the effective charge on the protonated amine nitrogen within the drug molecule. An effective charge on the quaternary amine is determined by the effect of the molecular environment (via through-bond, electronic, inductive, and through-space interactions) and the extent of the solvation of the molecule.

In the case of ions (i.e., protonated amines in small drug molecules, versus small ions), when an ion moves through a solvent, such as water, it experiences an impeding frictional force proportional to its speed. If one accepts that the Stokes’ relationship applies at the molecular scale, then a moving aqueous ion will reach a terminal speed known as the ‘drift speed’. The drift speed is achieved when the accelerating force of the ion is balanced by the viscous drag. Hence, it is the drift speed that governs the rate at which a charge can be transported. Molar conductivity decreases with increasing ion size, but this is not true for exceedingly small ions. Small ions, such as Li⁺ and Na⁺, generate a stronger electric field than larger ions, such as TEA. Because Li⁺ and Na⁺ drag water molecules as they migrate, these small cations are solvated to a greater extent and generate a larger hydrodynamic radius. Therefore, when one computes the estimated effective hydrodynamic radii, a Li⁺ ion drags approximately three water molecules, while a Na⁺ ion drags one water molecule, and potassium or larger ions, unless they have hydrogen bonding capacity (FON Bonds), do not readily drag along water molecules.

The presented model is purposely based on a low level of computational theory performing gas-phase calculations; higher levels of computational theory are not needed to unveil trends. The results obtained using Hartree–Fock (HF/321G) and the Chem3D property server are summarized in Table S1 and support the notion that the Connolly molecular area and the Connolly solvent-excluded volume order for small ions has the following trend: 3H₂O·Li⁺ > H₂O·Na⁺ > Rb⁺ > K⁺ > H₂O > Na⁺ > Ca²⁺ > Mg²⁺ > Li⁺. Hence, the hydrated sodium ion is larger in size than a non-hydrated potassium ion—computed atomic masses (Na⁺ hydrate 41.0 amu; versus K⁺ 39.1 amu).

In the case of a multi-electron system, such as Na⁺ and K⁺, each electron is attracted to the nucleus and experiences a Coulombic repulsion by the other electrons. The electron density between the nucleus and the electron of interest will reduce the nuclear charge acting on that electron. The net positive charge attracting the electron is known as the ‘effective nuclear charge’, Z_{eff}. \( Z_{eff} = Z - X \) where ‘Z’ is the number of protons in the nucleus and ‘X’ is the number of electrons between the nucleus and the electron of interest. Hence, an outer electron experiences a shielded nuclear charge but does not oppose the full Coulombic attraction of the nucleus. The effective charge is simply a way of expressing the net outcome of the nuclear attraction and the electronic repulsions in terms of a single equivalent charge at the center of the atom [23,24]. On the basis that the shielding of a nuclear charge occurs in a multi-electron system, alkyl groups covalently attached to the nitrogen atom in a quaternary ammonium ion will shield the formal +1 charge [1]. We approached the problem by using different methods to computationally compute effective charges on the atoms within a molecule where the amine is protonated.

2.2. Computing Atomic Charges

Here, we asked whether the concepts proposed previously [1] can be extended to the drug-hERG SAR. Many drugs and New Chemical Entities (NCEs) contain at least one amine functional group. Amines (primary, secondary, and tertiary), having a lone pair of electrons, can be protonated to afford a quaternary ammonium cation. Thus, an equilibrium between protonated and non-protonated forms exists at the pH values characteristic for each molecule. As illustrated experimentally and theoretically, Table S2, the substituent(s) attached to the amine inherently influences the observed pKa.

There are a variety of ways to computationally generate atomic charges [25]. The three different methods that were computed in this manuscript include: (1) the Mulliken population analysis that will partition the total +1 molecular charge amongst the atoms
within the molecule; (2) the natural population analysis (NBO) which uses core electrons, valence electrons, and electrons located in diffuse functions to partition the charge on the nitrogen; and (3) the Merz–Kollman–Singh (MKS) method which assigns point charges to fit the computed electrostatic potential to points on concentric spheres around each atom. Out of the three methods, the Mulliken and NBO were found to be more informative than the MKS. Regarding the Mulliken Population Analysis, Mulliken charges provide a way to estimate partial atomic charges from calculations carried out by computational chemistry via a linear combination of atomic orbitals (LCAO), a molecular orbital method routinely used as variables in linear regression, whereas the NBO analysis is based on a method that optimally transforms a given wave function into a localized form which corresponds to Lewis structure pictures where one has lone pairs and chemical bonds.

Because amines form weaker hydrogen bonds compared to alcohols, their boiling points, in general, are lower and their solubilities in water are less. Tertiary amines are least solvated, while primary amines are the most solvated. In addition, as represented in Figure 2, there is a correlation (R squared 0.92) between the experimental pKa and the computational values computed on the protonated nitrogen atom (NBO); the amine basicity is derived from a combination of inductive, steric, and solvation effects.

Researchers have used a number of different experimental techniques to evaluate drug-hERG interactions in vitro. Gonzalez et al. [26] reviewed cell-based assays used to analyze the properties of ion channels, including (i) electrophysiology (patch-clamp) binding assays; (ii) radioactive flux assays; (iii) redistribution membrane-potential dyes; and (iv) FRET-based voltage sensors. A variety of drugs that may prolong the QT interval and/or induce Torsades de Pointes have been summarized in Table 1 (compounds 1–54); these compounds represent the ‘learning compound set’. Their chemical structures are presented in the Supplementary Materials section, Figure S1. Experimentally determined IC\textsubscript{50} values for compounds (Table 2) were collected from the literature. The IC\textsubscript{50} values are derived from hERG-transfected HEK, COS-7, CHO or neuroblast cells, and hERG K\textsuperscript{+} channels expressed in Xenopus laevis oocytes or zebrafish model [27–55].

![Figure 2. Protonated amines atomic charge, pKa vs. HF/321G NBO data.](image-url)
Table 1. Compounds that may prolong QT and/or induce Torsades de Pointes.

| Drug                 | Classification          | Drug          | Classification          |
|----------------------|-------------------------|---------------|-------------------------|
| Amiodarone           | Antiarrhythmic          | Isradipine    | Anti-hypertensive       |
| Amitriptyline        | Anti-depressant         | Ketanserin    | Anti-hypertensive       |
| Astemizole           | Antihistamine           | Loratadine    | Antihistaminic          |
| Bepridil             | Anti-anginal            | Mesoridazine  | Antipsychotic           |
| Cetirizine           | Antihistaminic          | Mopsapride    | Peristaltic stimulant   |
| Chlorpromazine       | Antipsychotic           | Nicotine      | Anthelmintic            |
| Ciprofloxacin        | Anti-bacterial          | Nifedipine    | Anti-anginal            |
| Cisapride            | Peristaltic stimulant   | Nitrendipine  | Anti-hypertensive       |
| Clarithromycin       | Anti-bacterial          | Ondansetron   | Antiemetic              |
| Clozapine            | Antipsychotic           | Paroxetine    | Anti-depressant         |
| Cocaine              | Topical anesthetic      | Pentamidine   | Anti-protozoal          |
| Desipramine          | Anti-depressant         | Perhexiline   | Diuretic                |
| Diltiazem            | Anti-anginal            | Pimozone      | Antiipsychotic          |
| Diphenhydramine      | Antihistaminic          | Procainamide  | Cardiac depressant      |
| Domperidone          | Cardiac depressant      | Promethazine  | Antipschiatric          |
| Diphenhydramine      | Cardiac depressant      | Prucalopride  | Peristaltic stimulant   |
| Diphenhydramine      | Cardiac depressant      | Quinidine     | Cardiac depressant      |
| Diphenhydramine      | Cardiac depressant      | Renzapride    | Peristaltic stimulant   |
| Diphenhydramine      | Cardiac depressant      | Sertraline    | Anti-depressant         |
| Diphenhydramine      | Cardiac depressant      | Sotalol       | Anti-anginal            |
| Diphenhydramine      | Cardiac depressant      | Tamoxifen     | Anti-estrogen           |
| Diphenhydramine      | Cardiac depressant      | Terfenadine   | Antihistaminic          |
| Diphenhydramine      | Cardiac depressant      | Thiopizidaine | Antipsychotic           |
| Diphenhydramine      | Cardiac depressant      | Verapamil     | Anti-anginal            |

Table 2. Computational analysis using ab initio HF/321G, Mulliken, NBO, and MKS of protonated drug.

| DRUG                 | Mulliken  | NBO       | MKS       | MW      | In Vitro IC<sub>50</sub> (M) |
|----------------------|-----------|-----------|-----------|---------|-----------------------------|
| Amiodarone           | −0.79268  | −0.54778  | ND        | 644.36  | 0.1178 [49]; 1.0 [40]       |
| Amiodarone           | −0.80091  | −0.23399  | 0.07330   | 278.42  | 10.0 [30]                   |
| Astemizole           | −0.79546  | −0.55224  | −0.13528  | 459.59  | 0.001 [31]; 0.0009 [26]; 0.480 [28] |
| Astemizole           | −0.78551  | −0.54645  | −0.21160  | 355.46  | >30 [28]                    |
| Astemizole           | −0.78434  | −0.55278  | 0.07330   | 367.56  | 0.55 [31]; 0.6 [40] (ZF)    |
| Astemizole           | −0.79922  | −0.55743  | 0.06966   | 319.88  | 1.47 [30]                   |
| Astemizole           | −0.80141  | −0.70264  | −0.37912  | 331.35  | 0.0067 [30]; 0.0065 [29]; 0.0024 [27]; 0.018 [52]; 0.0094 [38] |
| Astemizole           | −0.79574  | −0.54571  | −0.04759  | 466.96  | 0.0024 [27]; 0.018 [52]; 0.0094 [38] |
| Astemizole           | −0.79433  | −0.16888  | −0.03182  | 748.98  | 720 [31]                   |
| Astemizole           | −0.79097  | −0.55892  | 0.14914   | 293.39  | 0.32 [30]                   |
| Astemizole           | −0.74627  | −0.55056  | −0.14587  | 304.37  | 7.2 [30]                    |
| Astemizole           | −0.81479  | −0.70178  | −0.08777  | 267.40  | 1.39 [30]                   |
| Astemizole           | −0.80148  | −0.55903  | 0.01192   | 415.54  | 17 [31]; 17.3 [30]         |
| Astemizole           | −0.80027  | −0.55679  | 0.08497   | 256.37  | 2.7 [45]                    |
| Astemizole           | −0.78074  | −0.54725  | −0.33518  | 312.44  | 25.7 [42]                   |
| Astemizole           | −0.82296  | −0.56875  | 0.10563   | 426.93  | 0.16 [31]                   |
| Astemizole           | −0.80126  | −0.12408  | −0.05770  | 280.39  | 6.5 ± 1.4 [37]             |
The compounds were computationally evaluated, and their data were also summarized in Table 2. The NBO values versus Mulliken were plotted to provide the electronic patterns (Figure 3A) for these compounds. As summarized in the flow chart (Scheme 1), a series of initial questions were asked to eliminate the compounds without amines and poor interactors. Question 1: Glibenclamide (23; 74 μM), loratadine (31; 0.17 μM), ondansetron (37; 0.81 μM), and pentamidine (39; 5–8 μM), blue points, do not contain an amine and are, therefore, not subjects for this scheme. Question 2: Amitriptyline (2; 10 μM), clarithromycin (9; 720 μM), doxepin (17; 7 μM), and erythromycin (19; >10 μM), Figure 3A, green points >7.0 μM, all exhibit high IC50 values and have an NBO < −0.45. Question 3: Isradipine (29;...
>10 µM), nifedipine (35; >50 µM), and nitrendipine (36; >10 µM), Figure 3A, orange points, exhibit low hERG affinity and possess a protonated nitrogen Mulliken charge >−0.90. Question 4: Compounds possessing a carboxylic acid are all low-affinity compounds. These compounds, Cetirizine (5; >30 µM), ciprofloxacin (7; 966 µM), and fexofenadine (20; 214 µM), are designated by red points but are embedded in the remaining data points in black, Figure 3A. In Figure 3B, the low-affinity interactors identified by questions 1–4 (colored points from Figure 3A) have been removed. This produces a plot with two distinct electronic patterns largely containing hERG inhibitors with low IC_{50} values. One group is composed of secondary amines (HF/321G NBO = −0.698 ± 0.009), while the other group is tertiary amines (HF/321G NBO = −0.555 ± 0.008). It is in these two electronic regions where potent hERG inhibitors are found.

![Diagram](A)  
**Figure 3.** (A): Table 1 Compounds HF/321G NBO vs. Mulliken Charge. (B): NBO vs. Mulliken Charge, secondary and tertiary amines; Table 1 protonated compounds after questions 1–5.
hERG Channel Flow-chart

Q1: From the test set, which compounds do not contain an amine?
- Glibenclamide
- Loratadine
- Ondansetron
- Pentamidine

Q2: From the amines, is the protonated nitrogen NBO < -0.45?
Yes (IC$_{50} > 7$ μM) → No (go to Q3)
- Amitriptyline
- Clarithromycin
- Doxepin
- Erythromycin

Q3: Is the protonated nitrogen Mulliken > -0.90?
Yes (IC$_{50} > 10$ μM) → No (go to Q4)
- Isradipine
- Nifedipine
- Nitrendipine

Q4: Is there a carboxylic acid in the molecule?
Yes (IC$_{50} > 4$ μM) → No (go to Q5)
- Cetirizine
- Ciprofloxacin
- Fexofenadine

Q5: Does the protonated N experience a field effect (shielding)?
Yes (IC$_{50} > 4$ μM) → No (go to Q6)
- Mosapride
- Nicotine

hERG Channel Flow-chart (continued)

Q6: Does the drug contain zero, one, two, three or more aromatic rings?

| Zero | One | Two | Three | Four |
|------|-----|-----|-------|------|
|      | Perhexiline (7.8) | Cocaine (7.2) | Bepridil (0.55) | Amiodarone (0.12) | Artemizine (0.001) |
|      | Felbamide (1.49)  | Procainamide (129) | Cisapride (0.007) | Chlorpromazine (1.47) | Domperidone 0.16 |
|      | Prucalopride (0.57) | Desipramine (1.39) | Desipramine (17) | Chlorpromazine (0.32) | Pimozide (0.02) |
|      | Ramipril (0.019)  | Diltiazem (17)  | Dilphenylhydantoin (2.7) | Droperidol (0.032) | Average = 0.04 μM |
|      | Sotalol (343)     | Disopyramide (25.7) | Disopyramide (25.7) | Halofantrine (0.2) | Average = 0.04 μM |
|      | Average = 81.9 μM | Fluoxetine (3.1) | Fluoxetine (3.1) | Ketanserin (0.28) | Average = 0.04 μM |
|      |                   | Granisetron (3.73) | Granisetron (3.73) | Mesoridazine (0.32) | Average = 0.04 μM |
|      |                   | Hapoperidol (0.027) | Hapoperidol (0.027) | Promethazine (0.73) | Average = 0.04 μM |
|      |                   | Hydroxyzine (0.18) | Hydroxyzine (0.18) | Tamoxifen (1.2) | Average = 0.04 μM |
|      |                   | Imipramine (3.4) | Imipramine (3.4) | Terfenadine (0.30) | Average = 0.04 μM |
|      |                   | Paroxetine (0.45) | Paroxetine (0.45) | Thioridazine (0.033) | Average = 0.04 μM |
|      |                   | Pyrilamine (6.0) | Pyrilamine (6.0) | Overall decrease in | Average = 0.04 μM |
|      |                   | Quinidine (0.32) | Quinidine (0.32) | hERG IC$_{50}$ value |                    |
|      |                   | Setraline (0.21) | Setraline (0.21) |                    |                    |
|      |                   | Sotalol (ND) | Sotalol (ND) |                    |                    |
|      |                   | Terodiline (0.58) | Terodiline (0.58) |                    |                    |
|      |                   | Verapamil (0.20) | Verapamil (0.20) |                    |                    |
|      |                   | Average = 3.8 μM | Average = 3.8 μM |                    |                    |

Q7: For drugs with more than one aromatic ring, are they going in the same direction or are they going in different directions? What is the number of atoms away from the protonated amine? See Table S3

Scheme 1. hERG channel prediction flow chart for first compound set.

Within these two groups there are several outliers with a low affinity for hERG, Figure S2. Some outliers are identified by question 5: Does the protonated nitrogen experience a strong field effect? Nicotine (34; 245 μM) and mosapride (33; 4.8 μM) have statistically higher IC$_{50}$ values due to the strong field effect (shielding) [1]. Procainamide (42; 139 μM) and sotalol (49;
amiodarone ($\text{IC}_{50}$) also exhibit high $\text{IC}_{50}$ values. For sotalol, the increase in the $\text{IC}_{50}$ value appears to be due to intramolecular hydrogen bonding via the N-CH$_2$-CHOH-Ph functionality. The high $\text{IC}_{50}$ of procainamide may be attributable to the resonance structure of the aromatic amine with the amide and relative distance to the protonated alkyl amine. More selective SAR data would help evaluate this speculation as certain potent, low $\text{IC}_{50}$ compounds, such as cisapride, prucalopride, and renzapride, all contain Ar-NH$_2$ and alkyl amines.

As well as the alkyl environment surrounding the nitrogen, the presence of aromatic rings also has a major influence on the $\text{IC}_{50}$ values. For secondary amines containing two aromatic rings, the $\text{IC}_{50}$ ($\mu$M) trend was fluoxetine ($22; 3.1 \mu$M) > desipramine ($12; 1.39 \mu$M) > paroxetine ($38; 0.45 \mu$M) > terodiline ($51; 0.375 \mu$M) > sertraline ($48; 0.210 \mu$M)—summarized in Table S3. Attempts were conducted to look at other indicators, such as the molecular weight (267–415 amu), cLogP values, and number of heteroatoms. Irrespective of these parameters, the number of aromatic rings and the distance from the alkyl amine, whether or not the aromatic rings are in the same direction or opposite directions, and the alkyl amine environment are the major factors dictating the in vitro $\text{IC}_{50}$ values.

In general, as inferred from the data summarized in Scheme 1 Q6, a general trend of more potent, lower hERG $\text{IC}_{50}$ values occurs as one goes from two to three to four aromatic rings, respectively. In general, secondary amines have hERG $\text{IC}_{50}$ values greater than tertiary amines. Regarding the molecules containing two aromatic rings but with tertiary amines (Table S3), the $\text{IC}_{50}$ trend ranged from 0.0067 to 25.7 $\mu$M. The most potent ones having the aromatic groups being in an opposite direction and separated by 7–10 bond distances between the aromatic rings. Thus, in general, molecules containing a secondary amine, with two aromatic rings separated by different distances, have higher $\text{IC}_{50}$ values as compared to molecules that contain a tertiary amine with a similar aromatic connectivity/framework. The compounds with three aromatic rings and possessing tertiary amines provided the following trend: chlorpromazine ($6; 1.47 \mu$M) > tamoxifen ($50; 1.2 \mu$M) > promethazine ($43; 0.73 \mu$M) > ketanserin ($30; 0.38 \mu$M) > mesoridazine ($32; 0.32 \mu$M) = clozapine ($10; 0.32 \mu$M) > terfenadine ($52; 0.21 \mu$M) > halofantrine ($25; 0.20 \mu$M) > amiodarone ($1; 0.118 \mu$M) > thioridazine ($53; 0.036 \mu$M) > droperidol ($18; 0.032 \mu$M) – (range 0.032–1.47 $\mu$M). There is a general trend of more potent hERG inhibitors with three aromatic rings as compared to two aromatic rings.

Finally, the three examples of four aromatic rings and tertiary amines were domperidone ($16; 0.16 \mu$M), pimozone ($41; 0.018 \mu$M), and astemizole ($3; 0.001 \mu$M), all potent (< 0.1 $\mu$M) hERG inhibitors with aromatic groups in opposite directions and 7–10 bond distances from the aromatics. For example, the distance of the aromatic ring(s) from the amine nitrogen alkyl environment is as important as the alkyl environment surrounding the amine.

The current proposal does not explain the higher experimental $\text{IC}_{50}$ values for diltiazem ($13; 17 \mu$M) or disopyramide ($15; 25.7 \mu$M) —Figure S3—as one might predict these to be more potent inhibitors. For diltiazem, the increased $\text{IC}_{50}$ may be a function of the number and location of heteroatoms providing repulsive interactions, resulting in a high $\text{IC}_{50}$, but a systematic SAR is needed. While not a perfect comparison, if one compares disopyramide ($15; 25.7 \mu$M) to diphenhydramine ($14; 2.7 \mu$M), the distance of the 3,3-diaryomatic from the protonated amine, as compared to the distancing by 4,4-di-aromatic, gives diphenhydramine with an $\text{IC}_{50}$ of 2.7 $\mu$M. There is about a 10-fold reduction in the $\text{IC}_{50}$ from distancing by one methylene unit to afford a 4,4-aromatic connectivity. This provides some SAR information. Alternatively, the amide in disopyramide may be contributing intramolecular hydrogen bonding properties and causing the $\text{IC}_{50}$ to be greater than what one would predict from the computational data. Thus, while looking to make hERG inhibition predictions, one needs to perform the computational analysis, ask the questions in the flow chart, and assess the alkyl environment (secondary versus tertiary).

As summarized in Scheme 1, Q6: from the list of drugs that may prolong QT Table 1, the remaining drugs are grouped in terms of zero, one, two, three, and four aromatic rings. While a generalization, the amine as a secondary or a tertiary amine plays a factor, and
the number of aromatic groups disseminating from the amine functionality is also a factor. For example, going from left to right (Scheme 1, Q6; zero to four aromatic rings) has a general average trend of more potent hERG inhibitors in vitro (higher to lower IC$_{50}$ values, respectively). For all groups containing at least one aromatic ring, it is important to note that all contained at least one potent (<0.10 µM) inhibitor, e.g., group one, renzapride (47; 0.019 µM); group two, cisapride (8; 0.007 µM); group three, droperidol (18; 0.032 µM); and group four, astemizole (3; 0.001 µM).

Next, the alkyl environment around the amine was assessed. The compounds with two or more aromatic rings in the compound trigger the question: ‘are the aromatic rings going in the same or different directions, and what connectivity may they exhibit?’ (Q7). These considerations are summarized in Table S3 for the compounds that have two, three, and four aromatic groups, with their N-alkyl environment, relative distance from the amine, connectivity, and whether or not the groups are going in the same direction or opposite directions described. These again help to illustrate an important point; in cases where the aromatic rings are in opposite directions and within 7–10 bonds distance or so between the aromatic rings, all have very low IC$_{50}$ values (<0.1 µM), such as astemizole (3; 0.001 µM); pimozide (41; 0.018 µM); cisapride (8; 0.007 µM); haloperidol (26; 0.027 µM); and droperidol (18; 0.032 µM). If the aromatic rings are in the same direction, they have higher IC$_{50}$ ranges (0.1–1.0, 1.0–2.0, and 2.0–4.0 µM), but more experimental examples and a systematic SAR on a handful of chemical templates are needed.

2.4. Examples Illustrating the QA Ion Model

2.4.1. Example One: Terfenadine versus Fexofenadine

Terfenadine is a classic example of where the major route of metabolism is catalyzed by CYP (cytochrome P450 2D6 and 3A4)-mediated oxidation [56] to give fexofenadine and that the co-administration of a potent CYP3A4 inhibitor with terfenadine, such as ketoconazole, can result in elevated terfenadine plasma concentrations and lead to life-threatening results [57,58]. Terfenadine has a reported IC$_{50}$ for hERG of 31 to 300 nM (Table 2). The phase I metabolic biotransformation of terfenadine to the corresponding carboxylic acid (fexofenadine) is predicted by the QA ion model to greatly increase the IC$_{50}$ (Scheme 1, question 4). Indeed, the reported IC$_{50}$ for fexofenadine is more than 100-fold higher than for terfenadine [29]. As illustrated in Figure S4, the protonated terfenadine nitrogen is assessable to the channel pore, whereas in the case of fexofenadine, the carboxylic acid anion becomes attracted to the ammonium ion, Coulombic attraction interactions and sterically blocks interactions with the hERG pore region. Hence, giving rise to a much higher hERG IC$_{50}$. Thus, a strategy is to impede the accessibility of the amine to hERG.

2.4.2. Example Two: Cisapride, Mosapride, Prucalopride versus Renzapride

Using four different serotonin 5-hydroxytryptamine (5-HT4) receptor agonists (cisapride, mosapride, prucalopride, and renzapride), González et al. [27] described the investigations with hERG-transfected COS-7 cells utilizing the patch-clamp procedure. In summary, they were able to rank order the 5-HT4 potency to the hERG blockade: mosapride (33; 4800 nM) >> prucalopride (44; 570 nM) > renzapride (47; 180 nM) >> cisapride (8; 6.5–24 nM; [59–61]); mosapride did not produce a significant response in the recombinant hERG current. At first glance, when one compares the protonated forms of these four compounds, Figure S5, it may not be inherently obvious that mosapride is chemically distinct. However, by considering that a protonated amine can be influenced by field effects [1], then these 5-HT4 trends can be explained. The p-fluorobenzyl functionality in the protonated mosapride results in a strong field effect which alters the effective charge ($Z_{eff}$) on the nitrogen atom; a decrease in the effective formal charge (Z) results in a lower affinity, a higher IC$_{50}$, toward the hERG channel.
2.5. Testing the Ammonium Ion Model

The development of this proposed way to evaluate hERG interactions should allow medicinal chemists and ADME/DMPK researchers/scientists the opportunity to work together and make rational decisions about potential hERG liabilities prior to conducting extensive synthesis and animal testing. The ability to chemically dial-out and/or tone-down potential life-threatening drug-hERG interactions in vivo during NCE (New Chemical Entity) optimization should be of value to researchers and pharmaceutical companies.

The insights gained from the learning set of the compounds allows one to make predictions regarding a test set of drugs and/or metabolites; Table 3, (Compound Set; 55–91); the chemical structures are in Figure S6. First, using the question sequence Scheme S1, predictions were made and incorporated into Table 4. The predictions were made based upon the sequence of questions and comparisons to the examples in the learning set, i.e., overall reflecting the number of aromatic rings, connectivity, alkyl environment of the protonated amine, etc. Next, the literature data were sought, tabulated, and used to compare to the predictive ranges. All of the compounds in the test set contain an amine (Scheme S2), and only one compound (57; clozapine-N-oxide) had an NBO < −0.45; therefore, the prediction is > 7.0 µM with a reported experimental value of 133 µM.

Table 3. Second set of compounds that may prolong QT and/or induce Torsades de Pointes.

| Drug                  | Classification          | Drug                  | Classification          |
|-----------------------|-------------------------|-----------------------|-------------------------|
| Azimilide             | Class III antiarrhythmic| MDL 74,156            | 5-HT3 antagonist        |
| Bilastine             | 2nd Gen antihistamine   | Nicardipine           | Anti-Anginal            |
| Clozapine-N-oxide     | Metabolite              | Norastemizole         | Antihistamine calcium channel blocker |
| Desmethyl-clozapine   | Metabolite              | Prenylamine           |                         |
| O-desmethyl-astemizole| Metabolite              | Propafenone           | Antiarrhythmic          |
| Ebastine              | 2nd Gen H1 antagonist   | Rupatadine            | 2nd Gen antihistamine   |
| Carebastine           | Active metabolite       | Risperidone           | Antipsychotic Metabolite|
| Olanzapine            | Antipsychotic Metabolite|                     |                         |
| Desmethyl-olanzapine  | Antipsychotic Metabolite|                     |                         |
| 2-OH-methyl-olanzapine| Antipsychotic Metabolite|                     |                         |
| 2-Carboxy-Me-olanzapine| Metabolite             | Sildenafil             | Erectile dysfunction     |
| CJ-033466             | Metabolite              | Sparfloxacin          | Antibiotic              |
| Doxetilide            | Treat atrial flutter    | Sumatriptan           | Anti-migraine           |
| Dolasetron            | 5-HT3 antagonist        | Ziprasidone           | Antipsychotic           |
| DSP-6952              | 5-HT4 partial agonist   |                       |                         |
| Chlorphenamine        | Antihistamine Class III |                       |                         |
| E-4031                | Antiarrhythmic          |                       |                         |
| Endoxifen             | Metabolite              |                       |                         |
| Gatifloxacin          | Antibiotic              |                       |                         |
| Lidoflazine           | Calcium channel blocker |                       |                         |
| Levofloxacin          | Antibiotic              |                       |                         |
| Mibebradil            | for hypertension        |                       |                         |
| Mexiletine            | Antiarrhythmic agent    |                       |                         |
| MK-499                | Antiarrhythmic          |                       |                         |
Table 4. Computational analysis using ab initio HF/321G, Mulliken, NBO, molecular weight, and cLogP of protonated drug compound set two.

| Comp. # | Drug                        | Mulliken | NBO  | MW   | cLogP | Estimate | IC50  |
|---------|-----------------------------|----------|------|------|-------|----------|-------|
| 55-A    | azimilide N1                | −0.77112 | −0.5513 | 457.95 | 2.35  | 0.1–1.0  | 0.58; 0.6 [1] |
| 55-B    | azimilide N2                | −0.76740 | −0.5577 | —     | —     | —        | —     |
| 56      | Bilastine                   | −0.82271 | −0.5939 | 463.61 | 1.95  | >4.0     | 6.5–17.1 [51] |
| 57      | Clozapine-N-oxide           | −0.53326 | −0.2343 | 342.82 | 3.71  | >7.0     | 133.3 [30] |
| 58      | Desmethylclozapine          | −0.78796 | −0.7106 | 312.80 | 3.46  | 2.0–4.0  | 4.49 [30] |
| 59      | O-DesMe-Bilastine           | −0.77213 | −0.5507 | 444.54 | 5.50  | <0.1     | 0.01 [54] |
| 60      | Ebastine                    | −0.76819 | −0.5477 | 469.66 | 6.94  | <0.1     | 0.014; 0.30 [49] |
| 61      | Carebastine                 | −0.74827 | −0.6089 | 499.64 | 2.83  | >4.0     | No data |
| 62      | Olanzapine                  | −0.76581 | −0.3574 | 312.43 | 3.01  | 0.1–1.0  | 0.23 [30] |
| 63      | Desmethylolanzapine         | −0.78776 | −0.7104 | 298.41 | 2.75  | >4.0     | 14.2 [30] |
| 64      | 2-OH-Melanzapine            | −0.76572 | −0.5574 | 328.43 | 1.47  | 0.1–1.0  | 0.23, 11.6 [39] |
| 65      | 2-carboxylozanazine         | −0.76382 | −0.5566 | 342.42 | 0.27  | >4.0     | No data |
| 66      | CJ–033466                   | −0.77129 | −0.5458 | 377.91 | 3.26  | 1.0–2.0  | 2.6 [38] |
| 67      | Dofetilide                  | −0.78606 | −0.5572 | 441.56 | 1.99  | <0.1     | 0.007 [52] |
| 68      | Dolasetron                  | −0.77293 | −0.5571 | 324.37 | 1.18  | 4.0–6.0  | 5.95 [29] |
| 69      | DSP-6952                    | −0.76758 | −0.5489 | 454.95 | −0.26 | 0.1–1.0  | 0.27 [50] |
| 70      | Chlorphenamine              | −0.77488 | −0.5540 | 274.12 | 3.15  | 1.0–2.0  | 13 [35] |
| 71      | E-4031                      | −0.77456 | −0.5493 | 401.52 | 1.90  | <0.1     | 0.077 [29] |
| 72      | Endoxifen                   | −0.82062 | −0.7235 | 373.49 | 5.56  | 2.0–4.0  | 1.6 [47] |
| 73      | Gatifloxacin                | −0.83650 | −0.7429 | 375.39 | −0.27 | >6.0     | 50 [55] |
| 74-A    | Lidoflazine N1              | −0.76575 | −0.5478 | 491.62 | 4.79  | <0.1     | ≤0.037 [35] |
| 74-B    | Lidoflazine N2              | −0.79477 | −0.5730 | —     | —     | —        | —     |
| 75      | Levofoxacin                 | −0.82808 | −0.6079 | 361.37 | −0.51 | >4.0     | 915 [55] |
| 76      | Mibebradil                  | −0.77723 | −0.5471 | 495.63 | 6.36  | 1.0–2.0  | 1.43 [29] |
| 77      | Mexiletine                  | −0.84670 | −0.7498 | 179.26 | 2.57  | >6.0     | >>10 [31] |
| 78      | MK-499                      | −0.77257 | −0.5430 | 467.58 | 1.63  | <0.1     | 0.032 [31]; 0.090–0.107 |
| 79      | MDL 74,156                  | ND       | ND    | 326.39 | 0.74  | 4.0–6.0  | 12 [31] |
| 80      | Nicardipine                 | −0.97746 | −0.55123 | 480.54 | 5.23  | >10      | No data |
| 81      | Norastemizole               | −0.78844 | −0.7079 | 324.18 | 3.63  | <0.1     | 0.028 [54] |
| 82      | Prenylamine                 | −0.79110 | −0.6931 | 329.48 | 5.80  | 1.0–2.0  | 0.59 [35] |
| 83      | Propafenone                 | −0.82310 | −0.7145 | 341.44 | 3.64  | 1.0–2.0  | 2.0 [35] |
| 84      | Rupatadine                  | −0.75723 | −0.5493 | 415.96 | 5.06  | >4.0     | 8.1 [51] |
| 85      | Risperidone                 | −0.77038 | −0.5479 | 410.48 | 2.71  | <1.0     | 0.14 [31], 0.148 [30] |
| 86      | 9-hydroxy risperidone       | −0.77050 | −0.5480 | 426.48 | 1.07  | <1.0     | 1.3 [29] |
| 87      | Sertindole                  | −0.82424 | −0.5942 | 440.94 | 5.27  | <0.1     | 0.024 [31] |
| 88      | Sildenafil                  | −0.76843 | −0.5594 | 474.58 | 1.98  | 4.0–6.0  | 3.3 [30] |
| 89      | Sparfloxcin                 | −0.80527 | −0.7131 | 392.4  | −0.60 | >4.0     | 18 [31] |
| 90      | Sumatriptan                 | −0.81664 | −0.57292 | 396.42 | 0.74  | Est      | No data |
| 91      | Ziprasidone                 | −0.76981 | −0.5508 | 412.94 | 4.21  | 0.1–1.0  | 0.15 [31] |

Q3: Nicardipine (80) in the test set exhibits a protonable nitrogen with a Mulliken value <0.90 and thus has an estimate of >10 μM. Proceeding to question 4, the following compounds of the test set have a carboxylic acid moiety and therefore are predicted to have an IC50 greater than 6.0 μM: bilastine (56; 6–17 μM); carebastine (61; estimated at
>6.0 μM); 2-carboxy-methyl-olanzapine (65; estimated at >6.0 μM); gatifloxacin (73; 50 μM); levofloxacin (75; 915 μM); and sparfloxacin (89; 18 μM).

Compounds 56 and 61 are analogous to the ‘example one’ scenario previously discussed for terfenadine versus fexofenadine, where intramolecular attraction impedes the hERG interaction via intramolecular steric hindrance and Coulombic attraction, resulting in a higher IC50. In regard to the remaining compounds in the test set, the number of aromatic rings and relative connectivity (structures) are summarized in Scheme S1 and Table S4. A general trend of increased aromatic rings is associated with a lower hERG IC50, a trend seen with the learning set. Furthermore, the general trend of the aromatic rings being in different directions gives rise to lower IC50 values also holds true with the test set.

From the summary in Table S4, the following compounds from the test set were predicted to have IC50 values < 0.1 μM: O-desmethyl-astemizole (59; 0.01 μM), dofetilide (67; 0.007 μM), E-4031 (71; 0.0268 μM), MK-499 (78; 0.032 μM), lidoflazine (74; 0.037 μM), sertindole (87; 0.024 μM), and norastemizole (81; 0.028 μM). Dofetilide, E-4031, and MK-499 were all potent inhibitors. An interesting observation is that these last three compounds possess serious hERG liabilities to relieve the potential safety concern that accompanies predicted to have IC50 values between 0.1 and 1.0 μM (group one) include risperidone (85; 0.14 μM), ziprasidone (91; 0.15 μM), DSP-6952 (69; 0.271 μM), azimilide (85; 0.58 μM), prenylamine (82; 0.59 μM), 2-hydroxy-olanzapine (64; 0.23 μM), olanzapine (62; 0.231 μM), ebastine (60; 0.30 μM), and clozapine (10; 0.32 μM).

Group two (1.0–4.0 μM) includes: Sildenafil (88; 3.3 μM), 9-hydroxy-risperidone (86; 1.3 μM), mibebradil (76; 1.43 μM), endoxifen (72; 1.6 μM), propafenone (83; 2.0 μM), and CJ-033466 (66; 2.6 μM); and those at or > 4.0 μM are desmethyl clozapine (58; 4.49 μM), dolasetron (68; 5.95 μM), MDL 74,156 (79; 12.1 μM), chlorphenamine (70; 13 μM), desmethylolanzapine (63; 14.2 μM), and mexiletine (77; >10 μM). Regarding propafenone 83, one might predict it to be a lower IC50 value, but this example is similar to sotalol 49 where the intramolecular interactions with the alcohol functionality led to a higher IC50 value; so, the removal of the alcohol functionality should give rise to a more potent hERG inhibitor. In general, summarized in Table 4, the range estimates provide good predictability and can be a mechanism for go/no-go decision making during the drug development process and to guide the chemical modification of the drug substance.

The current work adds value to the preclinical safety/medicinal chemistry interface, as one can make rational drug design suggestions about how to modify an NCE that possesses serious hERG liabilities to relieve the potential safety concern that accompanies an hERG inhibitor. At the same time such modifications must strike a balance; one does not want to compromise the desired potency and other ADME properties of the NCE while optimizing the safety profile. Consequently, one could take different strategies, as proposed per the examples presented in Figure 4A, where astemizole (3; 0.001 μM)—a very potent hERG inhibitor—is predicted to have a statistically significant shift in the IC50 by removing a methylene -(CH2)- and thus affording a ‘field effect’ which should result in an increased IC50 (better safety profile) as compared to the parent astemizole. A similar safety improvement might be achieved by substituting the protonated nitrogen with a carbon atom. This modification would help to distinguish the importance of the amine functionality from the contributions of the aromatic skeleton. Lastly, one could incorporate a carboxylic acid into the molecule which should also give an increased hERG IC50.
inhibitor. In general, summarized in Table 4, the range estimates provide good predictability and can be a mechanism for go/no-go decision making during the drug development process and to guide the chemical modification of the drug substance.

The current work adds value to the preclinical safety/medicinal chemistry interface, as one can make rational drug design suggestions about how to modify an NCE that possesses serious hERG liabilities to relieve the potential safety concern that accompanies an hERG inhibitor. At the same time such modifications must strike a balance; one does not want to compromise the desired potency and other ADME properties of the NCE while optimizing the safety profile. Consequently, one could take different strategies, as proposed per the examples presented in Figure 4A, where astemizole (3; 0.001 μM)—a very potent hERG inhibitor—is predicted to have a statistically significant shift in the IC$_{50}$ by removing a methylene -CH$_2$- and thus affording a ‘field effect’ which should result in an increased IC$_{50}$ (better safety profile) as compared to the parent astemizole. A similar safety improvement might be achieved by substituting the protonated nitrogen with a carbon atom. This modification would help to distinguish the importance of the amine functionality from the contributions of the aromatic skeleton. Lastly, one could incorporate a carboxylic acid into the molecule which should also give an increased hERG IC$_{50}$.

As another example, clozapine (Figure 4B; 0.32 μM, 10) has the potential to be a safety concern. The removal of the methyl on the methyl-piperazine (58; experimentally confirmed, 4.49 μM), conversion of the nitrogen to a carbon, or replacement of the methylamine with a morpholine analog are predicted to have higher hERG IC$_{50}$ values as compared to the parent drug. On the other hand, the conversion of the methyl-piperazine to an ethyl-piperazine is predicted to result in an analog with a more potent (lower) IC$_{50}$ value, and a worse hERG safety profile. With regard to the example (Figure 4C) rupatadine, a drug that benefits from a ‘field effect’, the addition of a methylene group would disrupt this field effect and thus be predicted to have a significantly lower hERG IC$_{50}$ value (worse safety profile). Whereas Olanzapine (Figure 4D; 62, 0.231 μM), as an example, may be improved by converting to a benzyl functionality which should give an increased IC$_{50}$ value due to the ‘field effect’ or the conversion of the methyl-piperazine to a morpholine functionality with an improved, higher hERG IC$_{50}$ value. One could also remove the methyl group to afford a secondary amine which would produce a higher IC$_{50}$ value compared to the parent compound. This projection is confirmed by the experimental data; the measured IC$_{50}$ for compound 63 is 14.2 μM.

**Figure 4.** Examples of hERG interaction trend predictions, (A) Astemizole template. Removal of the -CH$_2$- should give rise to a molecule whose protonated nitrogen undergoes a ‘field effect’ and thus should give rise to a molecule that has a higher hERG IC$_{50}$. (B) Clozapine template. (C) Rupatadine template. (D) Olanzapine template.
As another example, clozapine (Figure 4B; 0.32 µM, 10) has the potential to be a safety concern. The removal of the methyl on the methyl-piperazine (58; experimentally confirmed, 4.49 µM), conversion of the nitrogen to a carbon, or replacement of the methyamine with a morpholine analog are predicted to have higher hERG IC₅₀ values as compared to the parent drug. On the other hand, the conversion of the methyl-piperazine to an ethyl-piperazine is predicted to result in an analog with a more potent (lower) IC₅₀ value, and a worse hERG safety profile. With regard to the example (Figure 4C) rupatadine 84, a drug that benefits from a ‘field effect’, the addition of a methylene group would disrupt this field effect and thus be predicted to have a significantly lower hERG IC₅₀ value (worse safety profile). Whereas Olanzapine (Figure 4D; 62, 0.231 µM), as an example, may be improved by converting to a benzyl functionality which should give an increased IC₅₀ value due to the ‘field effect’ or the conversion of the methyl-piperazine to a morpholine functionality with an improved, higher hERG IC₅₀ value. One could also remove the methyl group to afford a secondary amine which would produce a higher IC₅₀ value compared to the parent compound. This projection is confirmed by the experimental data; the measured IC₅₀ for compound 63 is 14.2 µM.

3. Methods

The computational methodology used herein was based upon calculations performed with Gaussian® (Gaussian, Inc.; Pittsburgh, PA, USA) [61]. All chemical structures were drawn using CS Chem-Draw Ultra® and copied into CS Chem3D Ultra® (Perkin Elmer; Waltham, MA, USA). A molecular mechanics (MM) minimization was performed with a root-mean-square (RMS) gradient of 0.01. Afterward, semi-empirical Austin-model (AM1) calculations were performed, and then low level ab initio (HF/3-21G) molecular orbital (MO) calculations were computed. Atomic charges were computed, and calculations were conducted using an HP Pavilion g7 Notebook PC. Data were tabulated from the output files and values plotted using GraphPad Prism 9.3.1 (1992-2021 GraphPad Software, LLC; San Diego CA, USA). Using known hERG literature in vitro data, comparisons to the computed theoretical data are presented.

4. Conclusions

The current work provides insights into how one may recognize the potential hERG liability in a lead molecule (NCE) that contains an alkyl-amine functionality and how rational chemical modifications may lead to compounds with a better hERG preclinical safety profile. The array of drugs with diverse chemical structures which have been investigated in this work supports the notion that there are multiple drug binding sites in the hERG pore, which adds complexity to the overall picture. More fundamental chemical information is needed to fully appreciate the overall hERG SAR. What has been presented herein is one approach. Two critical aspects need to be carefully and methodically studied: i) Carefully understanding the changes in the alkyl environment surrounding the amine while holding the aromatic framework constant; the m/z relationship is believed to be a function of the mass within four bond distances from the amine (not the entire mass of the compound). ii) Carefully probing the interactions of modified aromatic rings (i.e., electron withdrawing groups and electron donating groups, stereochemistry, etc.) More direct comparisons are needed, and future work in our lab will focus on the chemical synthesis and testing of analogs to further probe the hERG SAR. Lastly, when considering safety, it is also important to understand the extent and the chemical nature of the metabolism of the parent drug, which CYP’s and/or drug transporters are involved, etc. Other aspects are important, such as the route of the administered dose, frequency of dose, Cmax, Tmax, T½, protein binding, route of elimination, drug transporter interactions, DDI (drug–drug interactions), and pharmacodynamics (PD). Hopefully, insights from this manuscript and future work will translate into improved rational drug design for medicinal/ADME/DMPK scientists with hERG safety in mind during the NCE optimization process.
Funding: This research received no external funding.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms231810732/s1.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is summarized in Supplementary Materials Section.

Acknowledgments: M.F.W. thanks P.J. Rice and S. Nordeen for editorial suggestions. M.F.W. also thanks P. Reigan for help with generating Figure 1A.

Conflicts of Interest: The author has no conflicts of interest.

References
1. Wempe, M. Quaternary ammonium ions can externally block voltage-gated K+ channels. Establishing a theoretical and experimental model that predicts K+ and the selectivity of K+ over Na+ ions. J. Mol. Struct. 2001, 562, 63–78. [CrossRef]
2. Wang, W. MacKinnon R Cryo-EM Structure of the Open Human Ether-à-go-go-Related K+ Channel hERG. Cell 2017, 169, 422–430. [CrossRef] [PubMed]
3. Available online: https://www.chemicool.com/definition/quadrupole_mass_spectrometry.html (accessed on 5 September 2022).
4. Silverstein, R.M.; Bassler, G.C. Spectrometric identification of organic compounds. J. Chem. Educ. 1962, 39, 546. [CrossRef]
5. Ranjan, R.; Logette, E.; Marani, M.; Herzog, M.; Tàche, V.; Scantamburlo, E.; Buchillier, V.; Markram, H. A Kinetic Map of the Homomeric Voltage-Gated Potassium Channel (Kv) Family. Front. Cell. Neurosci. 2019, 13, 358. [CrossRef]
6. Kim, D.M.; Nimigean, C. Voltage-Gated Potassium Channels: A Structural Examination of Selectivity and Gating. Cold Spring Harb. Perspect. Biol. 2016, 8, a029231. [CrossRef] [PubMed]
7. Kurachi, Y.; Jan, Y.; Lazdunski, M. Potassium Ion Channels: Molecular Structure, Function, and Diseases, 1st ed.; Elsevier: Amsterdam, The Netherlands, 1999; ISBN 9780080585178.
8. Warmke, J.W.; Ganetzky, B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc. Natl. Acad. Sci. USA 1994, 91, 3438–3442. [CrossRef]
9. Curran, M.E.; Splawski, I.; Timothy, K.W.; Vincen, G.; Green, E.D.; Keating, M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995, 80, 795–803. [CrossRef]
10. Sanguinetti, M.C.; Jiang, C.; Curran, M.E.; Keating, M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995, 81, 299–307. [CrossRef]
11. Dolly, J.O.; Parcej, D.N. Molecular properties of voltage-gated K+ channels. J. Bioenerg. Biomembr. 1996, 28, 231–253. [CrossRef]
12. Doyle, D.A.; Morais Cabral, J.; Pfuetzner, R.A.; Kuo, A.; Gulbis, J.M.; Cohen, S.L.; Chait, B.T.; MacKinnon, R. The Structure of the Potassium Channel: Molecular Basis of K+ Conduction and Selectivity. Science 1998, 280, 69–77. [CrossRef]
13. Viskin, S. Long QT syndromes and torsade de pointes. Lancet 1999, 354, 1625–1633. [CrossRef]
14. Vilums, M.; Overman, J.; Klaasen, E.; Scheel, O.; Brussee, J.; Ijzerman, A.P. Understanding of molecular substructures that contribute to hERG K+ channel blockade: Synthesis and biological evaluation of E-4031 analogues. ChemMedChem 2011, 7, 107–113. [CrossRef]
15. Carvalho, J.F.S.; Louvel, J.; Doornbos, M.L.J.; Klaasen, E.; Yu, Z.; Brussee, J.; Ijzerman, A.P. Strategies to reduce hERG K+ channel blockade: Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide. J. Med. Chem. 2013, 56, 2828–2840. [CrossRef] [PubMed]
16. Louvel, J.; Carvalho, J.F.S.; Yu, Z.; Soethoudt, M.; Lenselink, E.B.; Klaasen, E.; Brussee, J.; Ijzerman, A.P. Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: A case of clofilium Analogues. J. Med. Chem. 2013, 56, 9427–9440. [CrossRef] [PubMed]
17. Yu, H.-B.; Zou, B.-Y.; Wang, X.-L.; Li, M. Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay. Acta Pharmacol. Sin. 2016, 37, 111–123. [CrossRef] [PubMed]
18. Negami, T.; Araki, M.; Okuno, Y.; Terada, T. Calculation of absolute binding free energies between the hERG channel and structurally diverse drugs. Sci. Rep. 2019, 9, 16886. [CrossRef]
19. Ding, W.; Nan, Y.; Wu, J.; Han, C.; Xin, X.; Li, S.; Liu, H.; Zhang, L. Combining multi-dimensional molecular fingerprints to predict the hERG cardiototoxicity of compounds. Comput. Biol. Med. 2022, 144, 105390. [CrossRef]
20. Butler, A.S.; Hellwell, M.V.; Zhang, Y.; Hancox, J.C.; Dempsey, C.E. An Update on the Structure of hERG. Front. Pharmacol. 2020, 10, 1572. [CrossRef]
21. Hansch, C.; Fujita, T. π-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure. J. Am. Chem. Soc. 1964, 86, 1616–1626. [CrossRef]
22. Hammett, L.P. Physical Organic Chemistry; McGraw-Hill: New York, NY, USA, 1940.
23. Humiston, B. General Chemistry, 4th ed.; John Wiley & Sons, Inc.: New York, NY, USA, 1986; Chapter 4.
24. Atkins, P.W. Physical Chemistry, 4th ed.; W. H. Freeman and Company: New York, NY, USA, 1990; Chapter 13; p. 366.
25. Foresman, J.B.; Frisch, A.E. Exploring Chemistry with Electronic Structure Method, 2nd ed.; Gaussian, Inc.: Pittsburgh, PA, USA, 1996.
26. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Zakrzewski, V.G.; Montgomery, J.A.; Stratmann, R.E.; Burant, J.C.; et al. Gaussian 98W (Revision A.7); Gaussian, Inc.: Pittsburgh, PA, USA, 1998.

27. E. González, J.; Oades, K.; Leychikis, Y.; Harootunian, A.; A. Negulescu, P. Cell-based assays and instrumentation for screening ion-channel targets. Drug Discov. Today 1999, 4, 431–439. [CrossRef]

28. Potet, F.; Bouyssou, T.; Escande, D.; Barò, I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-go-go K+ channel. J. Pharmacol. Exp. Ther. 2001, 299, 1007–1012. [PubMed]

29. Taglialetela, M.; Pannacchine, A.; Castaldo, P.; Giorgio, G.; Zhou, Z.; January, C.T.; Genovese, A.; Marone, G.; Annunziato, L. Molecular basis for the lack of hERG K+ channel block-related cardiotoxicity by the hERG receptor blocker cetrizine compared with other second-generation antagonists. Mol. Pharmacol. 1998, 54, 113–121. [CrossRef] [PubMed]

30. Cavalli, A.; Poluzzi, E.; De Ponti, F.; Recanatini, M. Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome: Insights from a CoMFA Study of HERG K+ Channel Blockers. J. Med. Chem. 2002, 45, 3844–3853. [CrossRef] [PubMed]

31. Ekins, S.; Crumb, W.J.; Sarazan, R.D.; Wikle, J.H.; Wrighton, S.A. Three-Dimensional Quantitative Structure-Activity Relationship for Inhibition of Human Ether-a-Go-Go-Related Gene Potassium Channel. J. Pharmacol. Exp. Ther. 2002, 301, 427–434. [CrossRef]

32. Roche, O.; Trube, G.; Zuege, J.; Pfimlin, P.; Alanine, A.; Schneider, G. A Virtual Screening Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries. ChemBioChem 2002, 3, 455–459. [CrossRef]

33. Thomas, D.; Gut, B.; Wendt-Nordahl, G.; Kiehn, J. The Antidepressant Drug Fluoxetine Is an Inhibitor of Human Ether-A-Go-Related Gene (HERG) Potassium Channels. J. Pharmacol. Exp. Ther. 2002, 300, 543–548. [CrossRef]

34. Ridley, J.M.; Milnes, J.T.; Benest, A.V.; Masters, J.D.; Witchell, H.J.; Hancox, J.C. Characterisation of recombinant HERG K+ channel blockade by the Class la antiarrhythmic flecainide. Biochem. Biophys. Res. Commun. 2003, 306, 388–393. [CrossRef]

35. Kuryshchev, V.A.; Ficker, E.; Wang, L.; Hawryluk, P.; Dennis, A.T.; Wible, B.A.; Brown, A.M.; Kang, J.; Chen, X.-L.; Sawamura, K.; et al. Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking. J. Pharmacol. Exp. Ther. 2004, 312, 316–323. [CrossRef]

36. Katchman, A.N.; Koerner, J.; Tosaka, T.; Woosley, R.L.; Ebert, S.N. Comparative Evaluation of HERG Currents and QT Intervals following Challenge with Suspected Torsadogenic and Nontorsadogenic Drugs. J. Pharmacol. Exp. Ther. 2006, 316, 1098–1106. [CrossRef]

37. Martin, R.L.; Su, Z.; Limberis, J.T.; Palmatier, J.D.; Cowart, M.D.; Cox, B.F.; Gintant, G.A. In vitro preclinical cardiovascular safety studies of a novel 5-HT4 receptor agonist, DSP-6952. Int. J. Mol. Sci. 2018, 20, 826. [CrossRef] [PubMed]

38. Duncan, R.S.; McPate, M.J.; Ridley, J.M.; Gao, Z.; James, A.F.; Leishman, D.J.; Leaney, J.L.; Witchel, H.J.; Hancox, J.C. Inhibition of Human Ether-a-Go-Go-Related Gene (hERG) Channel Activity by Drug Classes Using a Cell-Based Assay. J. Mol. Cell. Cardiol. 2007, 42, 525–534. [PubMed]

39. Roche, O.; Trube, G.; Zuege, J.; Pfimlin, P.; Alanine, A.; Schneider, G. A Virtual Screening Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries. ChemBioChem 2002, 3, 455–459. [CrossRef]

40. Katchman, A.N.; Koerner, J.; Tosaka, T.; Woosley, R.L.; Ebert, S.N. Comparative Evaluation of HERG Currents and QT Intervals following Challenge with Suspected Torsadogenic and Nontorsadogenic Drugs. J. Pharmacol. Exp. Ther. 2006, 316, 1098–1106. [CrossRef]

41. Mittelstadt, S.W.; Hemenway, C.L.; Craig, M.P.; Hove, J.R. Evaluation of zebrafish embryos as a model for assessing inhibition of the HERG potassium channel. J. Pharmacol. Toxicol. Methods 2012, 66, 525–534. [CrossRef] [PubMed]

42. Jo, S.-H.; Hong, H.-K.; Chong, S.H.; Lee, H.S.; Choe, H. H1 antihistamine drug promethazine directly blocks hERG K+ channel. J. Pharmacol. Exp. Ther. 2009, 300, 427–439. [CrossRef]

43. Lee, B.H.; Lee, S.H.; Chu, D.; Hyun, J.W.; Choe, H.; Choi, B.H.; Jo, S.-H. Effects of the histamine H1 receptor antagonist hydroxyzine on hERG K+ channels and cardiac action potential duration. Acta Pharmacol. Sin. 2011, 32, 1128–1137. [CrossRef]

44. El Harchi, A.; Zhang, Y.H.; Hussein, L.; Dempsey, C.E.; Hancox, J.C. Molecular determinants of hERG potassium channel inhibition by disopyramide. J. Mol. Cell. Cardiol. 2012, 52, 185–195. [CrossRef]

45. Lee, H.-A.; Kim, K.-S.; Hyun, S.-A.; Park, S.-G.; Kim, S.J. Wide Spectrum of Inhibitory Effects of Sertraline on Cardiac Ion Channels. Korean J. Physiol. Pharmacol. 2012, 16, 327–332. [CrossRef]

46. Takahara, A.; Fujiwara, K.; Ohtsuki, A.; Oka, T.; Namekata, I.; Tanaka, H. Effects of the antitussive drug cloperastine on ventricular repolarization in halothane-anesthetized guinea pigs. J. Pharmacol. Sci. 2012, 120, 165–175. [CrossRef]

47. Lee, S.H.; Sung, M.J.; Lee, H.M.; Chu, D.; Hahn, S.J.; Jo, S.H.; Choe, H.; Choi, B.H. Blockade of HERG Human K+ Channels by the Antidepressant Drug Paroxetine. Biol. Pharm. Bull. 2014, 37, 1495–1504. [CrossRef]

48. Chae, Y.J.; Lee, K.J.; Lee, H.J.; Sung, K.-W.; Jin-Sung, C.; Choi, J.-S.; Lee, E.H.; Hahn, S.J. Endoxifen, the active metabolite of tamoxifen, inhibits cloned hERG potassium channels. Eur. J. Pharmacol. 2015, 752, 1–7. [CrossRef] [PubMed]

49. Melgari, D.; Zhang, Y.; El Harchi, A.; Dempsey, C.E.; Hancox, J.C. Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide. J. Mol. Cell. Cardiol. 2015, 86, 42–53. [CrossRef] [PubMed]

50. Zhang, Y.; Colenso, C.K.; El Harchi, A.; Cheng, H.H.J.; Dempsey, C.E.; Hancox, J.C. Interactions between Amioda-rone and the hERG Potassium Channel Pore Determined With Mutagenesis and in Silico Docking. Biochem. Pharmacol. 2016, 113, 24–35. [CrossRef] [PubMed]

51. Tsubouchi, T.; Kunimatsu, T.; Tsujimoto, S.; Kiyoshi, A.; Katsura, Y.; Oku, S.; Chihara, K.; Mine, Y.; Yamada, T.; Shimizu, I.; et al. The in vitro pharmacology and non-clinical cardiovascular safety studies of a novel 5-HT4 receptor agonist, DSP-6952. Eur. J. Pharmacol. 2018, 826, 96–105. [CrossRef]
52. Cataldi, M.; Maurer, M.; Taglialetela, M.; Church, M.K. Cardiac safety of second-generation H1-antihistamines when up-dosed in chronic spontaneous urticaria. *Clin. Exp. Allergy* 2019, 49, 1615–1623. [CrossRef]

53. Orvos, P.; Kohajda, Z.; Szlovák, J.; Gazdag, P.; Árpádföly-Lovas, T.; Tóth, D.; Geramipour, A.; Tállosi, L.; Jost, N.; Varró, A.; et al. Evaluation of Possible Proarrhythmic Potency: Comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and Native $I_{Kr}$ Currents and on Cardiac Action Potential. *Toxicol. Sci.* 2018, 168, 365–380. [CrossRef]

54. Zhou, Z.; Gong, Q.; Epstein, M.L.; January, C.T. HERG channel dysfunction in human long QT syndrome. *J. Biol. Chem.* 1998, 273, 21061–21066. [CrossRef]

55. Kang, J.; Wang, L.; Chen, X.L.; Triggle, D.J.; Rampe, D. Interactions of a series of fluoroquinolone anti-bacterial drugs with the human cardiac K$^+$ channel hERG. *Mol. Pharmacol.* 2001, 59, 122–126. [CrossRef]

56. Jones, B.C.; Hyland, R.; Ackland, M.; Tyman, C.A.; Smith, D.A. Interaction of Terfenadine and Its Primary Metabolites with Cytochrome P450 2D6. *Drug Metab. Dispos.* 1998, 26, 875–882.

57. Honig, P.K.; Wortham, D.C.; Zamani, K.; Conner, D.P.; Mullin, J.C.; Cantilena, L.R. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. *JAMA* 1993, 269, 1513–1518. [CrossRef]

58. Goto, A.; Sakamoto, K.; Hagiwara-Nagasawa, M.; Kambayashi, R.; Chiba, K.; Nuno, Y.; Izumi-Nakaseko, H.A.; Sugiyama, A. Utilization of the Chronic Atrioventricular Block Cynomolgus Monkey as an in Vivo Model to Evaluate Drug Interaction-Associated Torsade De Pointes. *J. Pharmacol. Sci.* 2020, 142, 172–175. [CrossRef] [PubMed]

59. Mohammad, S.; Zhou, Z.; Gong, Q.; January, C.T. Blockage of the HERG human cardiac K$^+$ channel by the gastrointestinal prokinetic agent cisapride. *Am. J. Physiol. Circ. Physiol.* 1997, 273, H2534–H2538. [CrossRef] [PubMed]

60. Rampe, D.; Roy, M.-L.; Dennis, A.; Brown, A.M. A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG. *FEBS Lett.* 1997, 417, 28–32. [CrossRef]

61. Drolet, B.; Khalifa, M.; Daleau, P.; Hamelin, B.A.; Turgeon, J. Block of the Rapid Component of the Delayed Rectifier Potassium Current by the Prokinetic Agent Cisapride Underlies Drug-Related Lengthening of the QT Interval. *Circulation* 1998, 97, 204–210. [CrossRef]